Institutional Investor M33 Growth Sells $7.3M in Shares, Drops Below 5% Ownership
summarizeSummary
Institutional investor M33 Growth I L.P. sold $7.3 million worth of Oncology Institute shares, reducing its stake below 5% after a series of open market transactions.
check_boxKey Events
-
Major Stake Reduction
M33 Growth I L.P. sold an aggregate of 1,800,000 shares of common stock in open market transactions between May 8 and May 14, 2026.
-
Significant Proceeds
The sales generated approximately $7.3 million in proceeds for the institutional investor.
-
Below 5% Ownership
Following these sales, M33 Growth I L.P. and its affiliates now beneficially own 4.94% of the company's common stock, ceasing to be a 5% owner.
-
Timing Post-Positive News
This significant sale occurs after the company reported improved financial results for Q4 2025 and Q1 2026.
auto_awesomeAnalysis
M33 Growth I L.P., a significant institutional investor, has sold 1.8 million shares of Oncology Institute stock for approximately $7.3 million. This series of open market transactions, occurring between May 8 and May 14, 2026, has reduced their beneficial ownership to 4.94%, causing them to cease being a 5% owner. This substantial reduction in stake, representing over 26% of their prior holdings, signals a significant rebalancing or reduced conviction from a major investor, especially following recent positive financial reports from the company.
At the time of this filing, TOI was trading at $3.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $397.9M. The 52-week trading range was $2.02 to $4.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.